Overview and Scope
Skin cancer diagnostics refers to the processes and methods healthcare professionals use to identify and determine the presence of skin cancer in individuals. These diagnostics typically involve a combination of clinical examination, imaging techniques, and laboratory tests to evaluate suspicious skin lesions and assess the extent and characteristics of the cancer.
Sizing and Forecast
The skin cancer diagnostics market size has grown strongly in recent years. It will grow from $2.85 billion in 2023 to $3.11 billion in 2024 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to increased incidence of skin cancer, growing aging population, awareness and education programs, government initiatives for early detection..
The skin cancer diagnostics market size is expected to see strong growth in the next few years. It will grow to $4.24 billion in 2028 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period can be attributed to rising sun exposure awareness, personalized medicine approaches, telemedicine and remote monitoring, global expansion of healthcare infrastructure.. Major trends in the forecast period include integration of digital health platforms, innovative skin cancer drugs, multi-disciplinary approaches, dermatopathology innovations, patient education and awareness..
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/skin-cancer-diagnostics-global-market-report
Segmentation & Regional Insights
The skin cancer diagnostics market covered in this report is segmented –
1) By Cancer Type: Basal Cell Carcinoma, Squamous Cell Carcinoma, Malignant Melanoma, Other Cancer Types
2) By Type: Diagnosis, Therapeutics
3) By Application: Hospital, Clinic, Laboratory, Other Applications
North America was the largest region in the skin cancer diagnostics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the skin cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11914&type=smp
Major Driver Impacting Market Growth
The increase in the incidence of melanoma is expected to propel the growth of the skin cancer diagnostics market going forward. Melanoma is a type of skin cancer that develops in the cells that produce melanin, the pigment responsible for skin color, hair, and eyes. Skin cancer diagnostics are crucial in identifying and characterizing skin lesions, aiding in early detection, accurate diagnosis, and effective treatment planning for skin cancer. For instance, in 2023, according to the report published by the American Cancer Society Inc., a US-based nationwide voluntary health organization dedicated to eliminating cancer, the number of male individuals suffering from melanoma in the United States increased from 57,180 in 2022 to 58,120 in 2023. Furthermore, in March 2023, according to the American Society of Clinical Oncology, a US-based professional organization representing all oncology physicians, melanoma accounts for around 1% of all skin cancers diagnosed in the United States. Yet, it is responsible for most skin cancer mortality. Melanoma is expected to kill 7,990 people in the United States in 2023 (5,420 males and 2,570 women). Melanoma killed a total of 57,043 people worldwide in 2020. Therefore, an increase in incidences of melanoma is driving the growth of the skin cancer diagnostics market.
Key Industry Players
Major companies operating in the skin cancer diagnostics market report are Pfizer Inc., F. Hoffmann-La Roche Limited, Merck & Co., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Sanofi, Eli Lilly and Company, Canon Medical Systems Corporation, Amgen Inc., GE Healthcare, Daiichi Sankyo Company Limited., National Cancer Institute, Agilent Technologies Inc., bioMerieux SA, Teva Pharmaceutical Industries, Bruker Corp, Almirall, Genentech, Castle Biosciences, Sun Pharmaceutical Industries Limited., American Academy of Dermatology, Biolitec Ag, Alma Lasers, DermTech Inc., SkylineDx BV, DermLite LLC, AMLo Biosciences Limited.
The skin cancer diagnostics market report table of contents includes:
1. Executive Summary
2. Skin Cancer Diagnostics Market Characteristics
3. Skin Cancer Diagnostics Market Trends And Strategies
4. Skin Cancer Diagnostics Market – Macro Economic Scenario
5. Global Skin Cancer Diagnostics Market Size and Growth
.
.
.
32. Global Skin Cancer Diagnostics Market Competitive Benchmarking
33. Global Skin Cancer Diagnostics Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Skin Cancer Diagnostics Market
35. Skin Cancer Diagnostics Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
